An optimization study for targeted alpha therapy: Ion behaviours and dose calculations within ICRU-compact bone...

Area of Science:

• Nuclear medicine
• Medical physics
• Oncology

Background:

• Targeted Alpha Therapy (TAT) offers a promising treatment for late-stage cancers, particularly bone metastases.
• Alpha-emitting radioisotopes like Radium-223 (²²³Ra) and Actinium-225 (²²⁵Ac) are crucial in TAT for destroying tumorous tissue within bone.

Purpose of the Study:

• To optimize TAT by analyzing the interactions between alpha particles from key radioisotopes and bone tissue.
• To evaluate parameters including ion spacing, stopping power, dose calculations, and atomic displacement for enhanced therapeutic precision.

Main Methods:

• Simulations and calculations using CASP, SRIM, and ASTAR programs to determine mass stopping power and ionizing dose.
• Comparison of calculation results from different programs for accuracy.
• Tissue dose calculations using IDAC-Dose 2.1, incorporating radioisotope half-lives, administered activity, and integration time.

Main Results:

• Analysis of ion spacing, stopping power, and atomic displacement of alpha particles within bone tissue.
• Comparison of calculated mass stopping power and ionizing dose values across different simulation programs.
• Determination of tissue doses based on specific radioisotope properties and treatment parameters.

Conclusions:

• The study provides optimized parameters for Targeted Alpha Therapy in bone metastases treatment.
• Understanding alpha particle interactions is key to maximizing therapeutic efficacy and minimizing off-target effects.
• Results support the advancement of TAT for improved patient outcomes in bone cancer therapy.